> Detailanzeige

Martin-Babau, Jerome; Douillard, Jean-Yves; Dupuis, Olivier Jean Marie; Porneuf, Marc; Ramée, Jean François; Raoul, Jean-Luc; Deguiral, Philippe; Faroux, Roger; Gourlaouen, Alain; Miglianico, Laurent; Van Hulst, Sylvie; El Hannani, C.; Bassoulet, James; Stampfli, Claire; Riche, Christian; Marhuenda, Fanny; Deniel Lagadec, Delphine; Jestin Le Tallec, Veronique; Grude, Francoise; Metges, Jean-Philippe

Is panitumumab monotherapy safe in metastatic colorectal cancer patients over 70 years old?

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Is panitumumab monotherapy safe in metastatic colorectal cancer patients over 70 years old?
  • Beteiligte: Martin-Babau, Jerome; Douillard, Jean-Yves; Dupuis, Olivier Jean Marie; Porneuf, Marc; Ramée, Jean François; Raoul, Jean-Luc; Deguiral, Philippe; Faroux, Roger; Gourlaouen, Alain; Miglianico, Laurent; Van Hulst, Sylvie; El Hannani, C.; Bassoulet, James; Stampfli, Claire; Riche, Christian; Marhuenda, Fanny; Deniel Lagadec, Delphine; Jestin Le Tallec, Veronique; Grude, Francoise; Metges, Jean-Philippe
  • Erschienen: American Society of Clinical Oncology (ASCO), 2015
  • Erschienen in: Journal of Clinical Oncology
  • Sprache: Englisch
  • DOI: 10.1200/jco.2015.33.3_suppl.714
  • ISSN: 0732-183X; 1527-7755
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p> 714 </jats:p><jats:p> Background: Metastatic Colorectal Cancer (mCRC) often occurs in patients older than 70 years old. Monoclonal antibodies targeting EGFR have improved the outcome of mCRC patients. Panitumumab in monotherapy is indicated in wild-type K-RAS mCRC progressing disease following fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. Very few data are available in elderly patients receiving panitumumab. Methods: Based on the cohort of the Observatory of Cancer B PL in France, we studied the efficacy and tolerance of panitumumab. We retrospectively collected data from patients treated between July 2008 and January 2014 and older than age 70 and compared the results between two cohorts: one contained patients ages 70 to 74; the other contained patients age 75 and older. Results: 136 patients were identified. The median age was 77. The median number of course received was 7 infusions. There was no difference in outcomes between the patients of the two cohorts. Median overall survival was 6.16 months. Median PFS was 13 weeks. The older patients received less previous chemotherapy ligns than the younger with a statistical difference (p=0.023). Tolerance was acceptable with a skin toxicity rate of 67% and 11.5% of grade 3-4. No diarrhea or hypomagnesemia were reported. Conclusions: Our study shows that panitumumab is feasible in elderly patients "in the real world" and has comparable efficacy than in younger patients. </jats:p>
  • Zugangsstatus: Freier Zugang